Your session is about to expire
← Back to Search
KIN-3248 for Solid Tumors
Study Summary
This trial will study the effects of KIN-3248, an oral small molecule that inhibits the FGFR2 and/or FGFR3 genes, in adults with advanced tumors. The trial will evaluate the safety and tolerability of the drug, as well as its preliminary efficacy.
- Intrahepatic Cholangiocarcinoma
- Bladder Cancer
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I'm sorry, it seems that you did not provide a criterion for me to rewrite. Could you please provide me with a criterion?You must be at least 18 years old or older than the legal age in your area.You have advanced bile duct or bladder cancer, or any other advanced cancer.You are able to swallow pills or liquid medication without any medical issues.You are not currently pregnant or breastfeeding.Your tumor has a specific mutation in either the FGFR2 or FGFR3 gene.
- Group 1: Part A - dose escalation
- Group 2: Part B - dose expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the aggregate amount of individuals participating in this trial?
"Kinnate Biopharma are recruiting 120 eligible patients to carry out the trial. Two of their participating locations include Mayo Clinic Arizona in Phoenix, Arizona and UC San Diego Moores Cancer Center in La Jolla, California."
Has the FDA sanctioned KIN-3248 for therapeutic use?
"KIN-3248's safety is ranked a 1 since this is an early Phase 1 trial, meaning there are only a few studies attesting to its efficacy and protective properties."
Is it possible to register for this research endeavor?
"According to the clinicaltrials.gov database, this research project is in active search for study participants. Initially posted on April 18th 2022 and recently updated November 7th 2022, it remains open to new enrollees."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: < 48 hours
Share this study with friends
Copy Link
Messenger